ClinicalTrials.gg
Active, not recruitingNCT06062420Updated Sep 24, 2026

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

A Phase 2 interventional study of Dostarlimab and Belrestotug in Neoplasms, Head and Neck, sponsored by GlaxoSmithKline. Active, not recruiting at 108 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Enrollment
45th of 161
316 · median 160
Started
2023
with 16 others
Phase 2
41 of 167
3 open now
Primary completion
2026-09
later than 15 of 69 live
Registered
136th of 167
by date
Lead sponsor
5 of 167
GlaxoSmithKline

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 45th largest by enrollment of the 161 interventional ones that give a count, is one of 17 that started in 2023, is one of 41 in phase 2, reaches primary completion later than 15 of the 69 other live ones, and was the 136th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

03

Conditions studied

  • Neoplasms, Head and Neck

Browse trials for

Keywords

  • Dostarlimab
  • Belrestotug
  • Nelistotug
  • Remzistotug
  • PD-L1
  • HNSCC
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 316 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology)
  • Has measurable (target) disease based on 1.1 as determined by the investigator.
  • Has an performance status (ECOG PS) of 0 or 1
  • Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumor. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable.
  • Has tumor Programmed death ligand 1 () expression
  • If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results

Exclusion criteria

Exclusion Criteria:

  • Has received prior therapy with any , including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways.
  • Participants with previous (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
  • Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major vessel [carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as arteriovenous fistula).
  • Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC
  • Participants with any carcinomatous meningitis or and those with uncontrolled or symptomatic Central Nervous System (CNS)
  • Active disease that has required systemic disease-modifying or treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    Dostarlimab Monotherapy

    Drug: Dostarlimab

  • Experimental
    Sub study 1: Dostarlimab and Belrestotug

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Sub study 2: Dostarlimab and nelistotug

    Drug: Dostarlimab · Drug: Nelistotug

  • Experimental
    Sub study 3: Dosarlimab and Belrestotug and nelistotug

    Drug: Dostarlimab · Drug: Belrestotug · Drug: Nelistotug

  • Experimental
    Sub study 4: Dostarlimab and remzistotug

    Drug: Dostarlimab · Drug: Remzistotug

Interventions

  • Dostarlimab will be administered.

  • Belrestotug will be administered.

  • Nelistotug will be administered.

  • DrugRemzistotug

    Remzistotug will be administered.

07

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy

    Confirmed ORR is defined as the percentage of participants achieving confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs), treatment emergent Serious Adverse Events (SAE) and treatment emergent Adverse Events of Special Interest (AESI)

    Time frame: Up to approximately 24 months

  2. Number of Participants with TEAEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to approximately 24 months

  3. Number of Participants with Clinically Significant Findings in Vital signs, Electrocardiogram (ECG), and Laboratory test parameters

    Time frame: Up to approximately 24 months

08

Study locations

108 sites
  • GSK Investigational Site
    New Haven, Connecticut 06511, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    St Louis, Missouri 63110-1010, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Capital Federal, C1181ACH, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABI, Argentina
  • GSK Investigational Site
    Córdoba, 5000, Argentina
  • GSK Investigational Site
    Florida, B1602DQD, Argentina
  • GSK Investigational Site
    Mendoza, M5500AYB, Argentina
  • GSK Investigational Site
    San Juan, 5400, Argentina
  • GSK Investigational Site
    Santa Fe, 3000, Argentina
  • GSK Investigational Site
    Santo André, 09060-650, Brazil
  • GSK Investigational Site
    São Paulo, 01221-020, Brazil
  • GSK Investigational Site
    São Paulo, 01246-000, Brazil
  • GSK Investigational Site
    Calgary, Alberta T2N 5G2, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Herlev, Denmark
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Bordeaux, 33075, France
  • GSK Investigational Site
    Caen, 14075, France
  • GSK Investigational Site
    Marseille, 13005, France
  • GSK Investigational Site
    Paris, 75005, France
  • GSK Investigational Site
    Rouen, 76038, France
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60488, Germany
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45122, Germany
  • GSK Investigational Site
    Aachen, 52074, Germany
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Giessen, 35392, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Regensburg, 93053, Germany
  • GSK Investigational Site
    Ulm, 89075, Germany
  • GSK Investigational Site
    Panórama, Central Macedonia 552 36, Greece
  • GSK Investigational Site
    Haidari - Athens, 12462, Greece
  • GSK Investigational Site
    Marousi, Greece
  • GSK Investigational Site
    Győr, 9024, Hungary
  • GSK Investigational Site
    Kecskemét, 6000, Hungary
  • GSK Investigational Site
    Pécs, 7624, Hungary
  • GSK Investigational Site
    Rozzano, MI 20089, Italy
  • GSK Investigational Site
    Bari, 70124, Italy
  • GSK Investigational Site
    Bologna, 40139, Italy
  • GSK Investigational Site
    Florence, 50134, Italy
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Novara, 28100, Italy
  • GSK Investigational Site
    Padova, 35128, Italy
  • GSK Investigational Site
    Roma, 00144, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Aichi, 464-8681, Japan
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Hyōgo, 650-0017, Japan
  • GSK Investigational Site
    Osaka, 541-8567, Japan
  • GSK Investigational Site
    Saitama, 350-1298, Japan
  • GSK Investigational Site
    Shizuoka, 411-8777, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Oslo, 0379, Norway
  • GSK Investigational Site
    Bielsko-Biala, 43-300, Poland
  • GSK Investigational Site
    Katowice, 40-514, Poland
  • GSK Investigational Site
    Krakow, 31-826, Poland
  • GSK Investigational Site
    Przemyśl, 37-700, Poland
  • GSK Investigational Site
    Siedlce, 08-110, Poland
  • GSK Investigational Site
    Warsaw, 04-141, Poland
  • GSK Investigational Site
    Almada, 2801-951, Portugal
  • GSK Investigational Site
    Lisbon, 1649-035, Portugal
  • GSK Investigational Site
    Porto, 4099-001, Portugal
  • GSK Investigational Site
    Porto, 4200-072, Portugal
  • GSK Investigational Site
    Brasov, 500283, Romania
  • GSK Investigational Site
    Bucharest, 020142, Romania
  • GSK Investigational Site
    Bucharest, 022328, Romania
  • GSK Investigational Site
    Bucharest, 030171, Romania
  • GSK Investigational Site
    Bucharest, 30463, Romania
  • GSK Investigational Site
    Craiova, 200542, Romania
  • GSK Investigational Site
    Floreşti, 407280, Romania
  • GSK Investigational Site
    Iași, 700483, Romania
  • GSK Investigational Site
    Oradea, 410469, Romania
  • GSK Investigational Site
    Piteşti, 110283, Romania
  • GSK Investigational Site
    Suceava, 720214, Romania
  • GSK Investigational Site
    Daegu, 42601, South Korea
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 13620, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 138-736, South Korea
  • GSK Investigational Site
    Suwon Kyunggi-do, 443-721, South Korea
  • GSK Investigational Site
    Barcelona, 08023, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Jaén, 23007, Spain
  • GSK Investigational Site
    Madrid, 28010, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pozuelo de AlarcOn Madr, 28223, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain

Showing the first 100 of 108 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Sep 2026, 33 months.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 33 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 2, 2023
StartActual
Nov 14, 2023
Primary completionActual
Sep 10, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06062420
Lead sponsor
GlaxoSmithKline
Collaborators
iTeos Therapeutics
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Nov 14, 2023
Primary completion
Sep 10, 2026
Completion
Dec 31, 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belrestotug · Nelistotug

Start the discussion